Document is current
Any future updates will be listed below
-
Authors
Gingerich, Maria Cristina
Nair, Nisha
Azevedo, Jose F.
Samanta, Kamalika https://orcid.org/0000-0001-6456-601X
Kundu, Suman https://orcid.org/0000-0002-8591-1166
He, Biao
Gomes-Solecki, Maria https://orcid.org/0000-0002-3715-4543
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI139267)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R43 AI155211)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R44 AI167605)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 5 July 2023
Accepted: 23 October 2023
First Online: 15 February 2024
Competing interests
: MGS is President and CEO of Immuno Technologies, Inc. BH is President and CEO of CyanVac, LLC and holds patents that covers use of PIV5 vaccine delivery vectors. BH is President and CEO of CyanVac, LLC and holds equity of its affiliate as well as patents that covers use of PIV5 vaccine delivery vectors. MCG is an employee of CyanVac, LLC and holds equity of its affiliate. The other authors have no competing interests.
